Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SNDX Catalyst Timeline
Dated clinical, regulatory and corporate events for Syndax Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Syndax Pharmaceuticals, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How SNDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-12 | axatilimab | Phase 2 topline data readout | Phase 2 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Revuforj |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revumenib Small MoleculesMarketedNCT06226571 | Acute Myeloid Leukemia | Approved | ACTIVE NOT_RECRUITING | 1,033 | Feb 1, 2027 | ||||||
| Revumenib Small MoleculesMarketedNCT07563010 | Relapsed Adult AML | Approved | NOT YET_RECRUITING | 146 | Jun 1, 2031 | ||||||
| Revumenib Small MoleculesNCT07923071 | Relapsed/Refractory (R/R) Hematologic Malignancies | Phase 1 | NOT YET_RECRUITING | 18 | Jan 1, 2032 | ||||||
| Entinostat Small MoleculesCompletedNCT02437136 | Non-Small Cell Lung Cancer | Phase 1/2 | COMPLETED | 191 | Sep 29, 2022 | ||||||
| Revumenib Small MoleculesMarketedNCT05406817 | Acute Leukemia | Approved | COMPLETED | 9 | Nov 18, 2024 | ||||||
| Revumenib Small MoleculesMarketedNCT05326516 | Relapsed/Refractory Leukemias | Approved | COMPLETED | 30 | Jul 29, 2024 | ||||||
| Axatilimab BiologicsMarketedNCT03604692 | Chronic Graft-versus-host-disease | Approved | COMPLETED | 337 | Oct 18, 2024 | ||||||
| Axatilimab BiologicsNCT06132256 | Idiopathic Pulmonary Fibrosis | Phase 2 | COMPLETED | 145 | Sep 10, 2026 | ||||||
| Axatilimab BiologicsNot countedNCT03238027 | Solid Tumor | Phase 1 | COMPLETED | 45 | Nov 20, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every SNDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| revumenib BreakthroughPriorityFast Track+1 | acute myeloid leukemia | Phase 1b | 2026-11-04 | high rates of remission, MRD negativity, and encouraging survivalRead More | Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Podlesak DennisDirector | Option | 8,000 247,763 held | $11.81 | 10/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SNDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 8.5 % (-12.4 %) | 153.24 M | 8.15 M | 1.24% ( 100.00 K) |
Ownership Trends
SNDX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How SNDX ranks across every disease it competes in
SNDX News
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced the hiring of Aaron A. Ondrey as CFO, effective November 9, 2026. He received an inducement award to purchase 270,000 shares at $9.55 each, vesting over four years. This award aligns with NASDAQ Listing Rule 5635(c)(4) and aims to support his long-term commitment to the company.
Read more →Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced the grant of inducement awards for 213,500 shares to five new employees under its 2023 Inducement Plan. The stock options will vest over four years, starting with 25% after one year. This move supports the company's commitment to advancing innovative cancer therapies.
Read more →Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
Syndax Pharmaceuticals announced an investor event on December 14, 2026, during the ASH Annual Meeting. The event will feature discussions led by the management team and key opinion leaders on significant data presented at the meeting. A live webcast will also be available for those unable to attend in person.
Read more →Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
Syndax Pharmaceuticals announced the acceptance of 19 abstracts for the ASH 2026 meeting, including 7 for oral presentation. The abstracts emphasize the promising activity of revumenib in various acute leukemia settings and the potential of axatilimab in chronic GVHD. The company will host an investor event on December 14, 2026, to discuss the findings.
Read more →Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported strong financial results for Q3 2026, with total revenue of $83.3 million, an 82% increase from the previous year. Revuforj (revumenib) and Niktimvo (axatilimab-csfr) contributed significantly to this growth, with net revenues of $60.7 million and $67.4 million, respectively. The company anticipates presenting new clinical data in Q4 2026 that could further enhance its market position.
Read more →Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
Syndax Pharmaceuticals announced Aaron A. Ondrey as the new Chief Financial Officer, effective November 9, 2026. He succeeds Keith A. Goldan, who will retire but assist during the transition. Ondrey has over 25 years of experience in financial leadership within the biotechnology sector and is expected to enhance Syndax's financial strategy.
Read more →Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
Syndax Pharmaceuticals announced that Revuforj (revumenib) won the 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases. The drug is the first and only menin inhibitor approved for adults and children aged one year and older with relapsed or refractory acute leukemia. This recognition highlights the treatment's impact on aggressive acute myeloid and KMT2A-translocated leukemias.
Read more →Syndax Announces Participation in November Investor Conferences
Syndax Pharmaceuticals announced its participation in several upcoming investor conferences. CEO Michael A. Metzger and the management team will engage in fireside chats at events in Boston, New York, and London from November 10 to November 19, 2026. Live webcasts of these sessions will be available on the company's website.
Read more →Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
Syndax Pharmaceuticals plans to announce its third quarter 2026 financial results on November 2, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. A replay of the call will be available on their website for 90 days.
Read more →Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Syndax Pharmaceuticals announced that its menin inhibitor, Revuforj (revumenib), has been named one of TIME's Best Inventions of 2026 in the Medical and Healthcare category. This recognition highlights Revuforj's innovative approach in treating relapsed or refractory acute leukemia. The drug is the first approved menin inhibitor for both adults and children, showcasing its significant impact in oncology.
Read more →Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of annualized FVC decline. Despite the negative results, axatilimab demonstrated a safety profile consistent with previous studies. The company will not pursue further development of axatilimab for IPF but will continue its trials in chronic graft-versus-host disease (cGVHD).
Read more →Syndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals announced its participation in two upcoming investor conferences in September 2026. CEO Michael A. Metzger and the management team will engage in fireside chats at the Citi Biopharma Conference and the H.C. Wainwright Global Investment Conference. Webcasts of these discussions will be accessible on the company's website.
Read more →Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported second quarter 2026 total revenue of $73 million, marking a 92 percent year-over-year increase. Revuforj net revenue reached $54.7 million, up 91 percent from the prior year period. Niktimvo net revenue totaled $60.3 million, representing a 67 percent year-over-year rise. The company also highlighted expansion of its clinical pipeline with new assets targeting NSCLC and myelofibrosis.
Read more →Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Syndax Pharmaceuticals announced it will report its second quarter 2026 financial results on August 4, 2026. The company will also host a conference call and live audio webcast at 4:30 p.m. ET on the same day. Investors can access the webcast through the company's website, with a replay available for 90 days post-event.
Read more →Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Syndax Pharmaceuticals announced new pipeline assets during its R&D event today. The company selected SNDX-62122 for development in myelofibrosis and introduced SNDX-4321 for non-small cell lung cancer. A Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis is on track for topline data in the fourth quarter of 2026. These updates expand the firm's research portfolio with externally licensed and internally developed candidates.
Read more →Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Syndax Pharmaceuticals announced promising data from the Phase 1/2 SAVE trial, showcasing high response rates for its all-oral therapy combining Revuforj, decitabine/cedazuridine, and venetoclax in treating relapsed or refractory AML patients with specific mutations. The trial demonstrated an overall response rate of 88%, with a significant portion of patients achieving minimal residual disease negativity and a robust transplant rate. The findings were published in the Journal of Clinical Oncology, indicating potential advancements in treatment standards for menin-dependent acute leukemias.
Read more →